The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: An EORTC phase II study (08992)

P. Baas, A. Ardizzoni, F. Grossi, K. Nackaerts, G. Numico, E. Van Marck, M. Van De Vijver, F. Monetti, M. J A Smid-Geirnaerdt, N. Van Zandwijk, C. Debruyne, C. Legrand, G. Giaccone

Research output: Contribution to journalArticle

Abstract

We investigated the activity and toxicity of raltitrexed (Tomudex®) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaïve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m2 intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.

Original languageEnglish
Pages (from-to)353-357
Number of pages5
JournalEuropean Journal of Cancer
Volume39
Issue number3
DOIs
Publication statusPublished - Feb 2003

Fingerprint

Research
Neoplasms
Therapeutics
Neutropenia
Radiology
Nausea
Vomiting
Fatigue
Diarrhea
Outpatients
Confidence Intervals
Malignant Mesothelioma
raltitrexed
Pharmaceutical Preparations

Keywords

  • Malignant Pleural Mesothelioma, Tomudex, Phase II, EORTC

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma : An EORTC phase II study (08992). / Baas, P.; Ardizzoni, A.; Grossi, F.; Nackaerts, K.; Numico, G.; Van Marck, E.; Van De Vijver, M.; Monetti, F.; Smid-Geirnaerdt, M. J A; Van Zandwijk, N.; Debruyne, C.; Legrand, C.; Giaccone, G.

In: European Journal of Cancer, Vol. 39, No. 3, 02.2003, p. 353-357.

Research output: Contribution to journalArticle

Baas, P, Ardizzoni, A, Grossi, F, Nackaerts, K, Numico, G, Van Marck, E, Van De Vijver, M, Monetti, F, Smid-Geirnaerdt, MJA, Van Zandwijk, N, Debruyne, C, Legrand, C & Giaccone, G 2003, 'The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: An EORTC phase II study (08992)', European Journal of Cancer, vol. 39, no. 3, pp. 353-357. https://doi.org/10.1016/S0959-8049(02)00668-8
Baas, P. ; Ardizzoni, A. ; Grossi, F. ; Nackaerts, K. ; Numico, G. ; Van Marck, E. ; Van De Vijver, M. ; Monetti, F. ; Smid-Geirnaerdt, M. J A ; Van Zandwijk, N. ; Debruyne, C. ; Legrand, C. ; Giaccone, G. / The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma : An EORTC phase II study (08992). In: European Journal of Cancer. 2003 ; Vol. 39, No. 3. pp. 353-357.
@article{e4b7109a600b4d49bac8b4a51b11584f,
title = "The activity of raltitrexed (Tomudex{\circledR}) in malignant pleural mesothelioma: An EORTC phase II study (08992)",
abstract = "We investigated the activity and toxicity of raltitrexed (Tomudex{\circledR}) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemona{\"i}ve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m2 intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8{\%}, 95{\%} confidence interval (CI) 7.1-42.2{\%}) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.",
keywords = "Malignant Pleural Mesothelioma, Tomudex, Phase II, EORTC",
author = "P. Baas and A. Ardizzoni and F. Grossi and K. Nackaerts and G. Numico and {Van Marck}, E. and {Van De Vijver}, M. and F. Monetti and Smid-Geirnaerdt, {M. J A} and {Van Zandwijk}, N. and C. Debruyne and C. Legrand and G. Giaccone",
year = "2003",
month = "2",
doi = "10.1016/S0959-8049(02)00668-8",
language = "English",
volume = "39",
pages = "353--357",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma

T2 - An EORTC phase II study (08992)

AU - Baas, P.

AU - Ardizzoni, A.

AU - Grossi, F.

AU - Nackaerts, K.

AU - Numico, G.

AU - Van Marck, E.

AU - Van De Vijver, M.

AU - Monetti, F.

AU - Smid-Geirnaerdt, M. J A

AU - Van Zandwijk, N.

AU - Debruyne, C.

AU - Legrand, C.

AU - Giaccone, G.

PY - 2003/2

Y1 - 2003/2

N2 - We investigated the activity and toxicity of raltitrexed (Tomudex®) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaïve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m2 intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.

AB - We investigated the activity and toxicity of raltitrexed (Tomudex®) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaïve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m2 intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.

KW - Malignant Pleural Mesothelioma, Tomudex, Phase II, EORTC

UR - http://www.scopus.com/inward/record.url?scp=0037304998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037304998&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(02)00668-8

DO - 10.1016/S0959-8049(02)00668-8

M3 - Article

C2 - 12565988

AN - SCOPUS:0037304998

VL - 39

SP - 353

EP - 357

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -